NovoCure Ltd — Director's Dealing 2019

Mar 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-03-22

Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-22	Restricted Share Units	A	24554	$0.00	Acquired	942860	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-22	Options to Buy Ordinary Shares	$47.04	A	44953	Acquired	2029-03-21	Ordinary Shares (44953)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.

F2: Options to buy 44,953 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.